<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Freiburger S</submitter><funding>DFG Clinician Scientist Program OrganAge</funding><funding>Deutsche Forschungsgemeinschaft</funding><pagination>137</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11273042</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(5)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Left ventricular assist devices (LVAD) and extracorporeal membrane oxygenation (ECMO) are well established therapies in heart failure (HF) management. Their use is generally associated with a sudden increase in inflammatory mediators, which are often already elevated in patients with HF prior to device implantation. An exaggerated release of proinflammatory cytokines is associated with organ dysfunction and increased mortality. Hemoadsorption has been shown to reduce inflammatory mediators during cardiopulmonary bypass.&lt;h4>Objective&lt;/h4>To investigate the role of hemoadsorption during the management of acute or chronic heart failure with mechanical circulatory support and its impact on survival.&lt;h4>Methods&lt;/h4>We systematically searched MEDLINE selecting all studies comp</pubmed_abstract><journal>Reviews in cardiovascular medicine</journal><pubmed_title>Hemoadsorption in Heart Failure Requiring Mechanical Circulatory Support-A Systematic Review and Meta-Analysis.</pubmed_title><pmcid>PMC11273042</pmcid><funding_grant_id>413668513</funding_grant_id><funding_grant_id>512648189</funding_grant_id><pubmed_authors>Schulze PC</pubmed_authors><pubmed_authors>Farber G</pubmed_authors><pubmed_authors>Doenst T</pubmed_authors><pubmed_authors>Tasoudis P</pubmed_authors><pubmed_authors>Franz M</pubmed_authors><pubmed_authors>Kirov H</pubmed_authors><pubmed_authors>Freiburger S</pubmed_authors><pubmed_authors>Diab M</pubmed_authors><pubmed_authors>Caldonazo T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Hemoadsorption in Heart Failure Requiring Mechanical Circulatory Support-A Systematic Review and Meta-Analysis.</name><description>&lt;h4>Background&lt;/h4>Left ventricular assist devices (LVAD) and extracorporeal membrane oxygenation (ECMO) are well established therapies in heart failure (HF) management. Their use is generally associated with a sudden increase in inflammatory mediators, which are often already elevated in patients with HF prior to device implantation. An exaggerated release of proinflammatory cytokines is associated with organ dysfunction and increased mortality. Hemoadsorption has been shown to reduce inflammatory mediators during cardiopulmonary bypass.&lt;h4>Objective&lt;/h4>To investigate the role of hemoadsorption during the management of acute or chronic heart failure with mechanical circulatory support and its impact on survival.&lt;h4>Methods&lt;/h4>We systematically searched MEDLINE selecting all studies comp</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2026-04-15T03:20:20.071Z</modification><creation>2026-04-15T03:14:58.569Z</creation></dates><accession>S-EPMC11273042</accession><cross_references><pubmed>39076733</pubmed><doi>10.31083/j.rcm2405137</doi></cross_references></HashMap>